565 related articles for article (PubMed ID: 15057430)
21. Survival stratification panel of colorectal carcinoma with combined expression of carcinoembryonic antigen, matrix metalloproteinases-2, and p27 kip1.
Li M; Li JY; Zhao AL; He JS; Zhou LX; Li YA; Gu J
Dis Colon Rectum; 2007 Nov; 50(11):1887-98. PubMed ID: 17882488
[TBL] [Abstract][Full Text] [Related]
22. Influence of tumor localization on the prognostic value of P53 protein in colorectal adenocarcinomas.
Diez M; Medrano M; Mugüerza JM; Ramos P; Hernandez P; Villeta R; Martín A; Noguerales F; Ruiz A; Granell J
Anticancer Res; 2000; 20(5C):3907-12. PubMed ID: 11268475
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies.
Scartozzi M; Bearzi I; Berardi R; Mandolesi A; Fabris G; Cascinu S
J Clin Oncol; 2004 Dec; 22(23):4772-8. PubMed ID: 15570078
[TBL] [Abstract][Full Text] [Related]
24. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
[TBL] [Abstract][Full Text] [Related]
25. Vascular endothelial growth factor receptor expression as a prognostic marker for survival in colorectal cancer.
Okita NT; Yamada Y; Takahari D; Hirashima Y; Matsubara J; Kato K; Hamaguchi T; Shirao K; Shimada Y; Taniguchi H; Shimoda T
Jpn J Clin Oncol; 2009 Sep; 39(9):595-600. PubMed ID: 19535387
[TBL] [Abstract][Full Text] [Related]
26. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.
Kemeny N; Garay CA; Gurtler J; Hochster H; Kennedy P; Benson A; Brandt DS; Polikoff J; Wertheim M; Shumaker G; Hallman D; Burger B; Gupta S
J Clin Oncol; 2004 Dec; 22(23):4753-61. PubMed ID: 15570076
[TBL] [Abstract][Full Text] [Related]
27. Posttreatment TNM staging is a prognostic indicator of survival and recurrence in tethered or fixed rectal carcinoma after preoperative chemotherapy and radiotherapy.
Chan AK; Wong A; Jenken D; Heine J; Buie D; Johnson D
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):665-77. PubMed ID: 15708244
[TBL] [Abstract][Full Text] [Related]
28. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
Gertler R; Rosenberg R; Stricker D; Friederichs J; Hoos A; Werner M; Ulm K; Holzmann B; Nekarda H; Siewert JR
J Clin Oncol; 2004 May; 22(10):1807-14. PubMed ID: 15143073
[TBL] [Abstract][Full Text] [Related]
29. Reduced expression of Apaf-1 in colorectal adenocarcinoma correlates with tumor progression and aggressive phenotype.
Paik SS; Jang KS; Song YS; Jang SH; Min KW; Han HX; Na W; Lee KH; Choi D; Jang SJ
Ann Surg Oncol; 2007 Dec; 14(12):3453-9. PubMed ID: 17882496
[TBL] [Abstract][Full Text] [Related]
30. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
[TBL] [Abstract][Full Text] [Related]
31. Preoperative chemoradiotherapy and total mesorectal excision surgery for locally advanced rectal cancer: correlation with rectal cancer regression grade.
Wheeler JM; Dodds E; Warren BF; Cunningham C; George BD; Jones AC; Mortensen NJ
Dis Colon Rectum; 2004 Dec; 47(12):2025-31. PubMed ID: 15657650
[TBL] [Abstract][Full Text] [Related]
32. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumors of the colon and rectum.
Mosnier JF; Perret AG; Vindimian M; Dumollard JM; Balique JG; Perpoint B; Boucheron S
Arch Pathol Lab Med; 1996 Jul; 120(7):654-9. PubMed ID: 8757470
[TBL] [Abstract][Full Text] [Related]
33. Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: A clinicopathologic study of 264 patients.
Baldus SE; Zirbes TK; Hanisch FG; Kunze D; Shafizadeh ST; Nolden S; Mönig SP; Schneider PM; Karsten U; Thiele J; Hölscher AH; Dienes HP
Cancer; 2000 Apr; 88(7):1536-43. PubMed ID: 10738210
[TBL] [Abstract][Full Text] [Related]
34. The prevalence and clinicopathologic correlate of p16INK4a, retinoblastoma and p53 immunoreactivity in locally advanced urinary bladder cancer.
Tzai TS; Tsai YS; Chow NH
Urol Oncol; 2004; 22(2):112-8. PubMed ID: 15082007
[TBL] [Abstract][Full Text] [Related]
35. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
[TBL] [Abstract][Full Text] [Related]
36. Expression of annexin A1 in esophageal and esophagogastric junction adenocarcinomas: association with poor outcome.
Wang KL; Wu TT; Resetkova E; Wang H; Correa AM; Hofstetter WL; Swisher SG; Ajani JA; Rashid A; Hamilton SR; Albarracin CT
Clin Cancer Res; 2006 Aug; 12(15):4598-604. PubMed ID: 16899607
[TBL] [Abstract][Full Text] [Related]
37. Clinical implications of fibroblast activation protein in patients with colon cancer.
Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
[TBL] [Abstract][Full Text] [Related]
38. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival.
Yoo PS; Sullivan CA; Kiang S; Gao W; Uchio EM; Chung GG; Cha CH
Ann Surg Oncol; 2009 Jan; 16(1):200-7. PubMed ID: 19009247
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma.
Sinicrope FA; Hart J; Michelassi F; Lee JJ
Clin Cancer Res; 1995 Oct; 1(10):1103-10. PubMed ID: 9815900
[TBL] [Abstract][Full Text] [Related]
40. DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study.
Bazan V; Migliavacca M; Zanna I; Tubiolo C; Corsale S; Calò V; Amato A; Cammareri P; Latteri F; Grassi N; Fulfaro F; Porcasi R; Morello V; Nuara RB; Dardanoni G; Salerno S; Valerio MR; Dusonchet L; Gerbino A; Gebbia N; Tomasino RM; Russo A
J Cancer Res Clin Oncol; 2002 Dec; 128(12):650-8. PubMed ID: 12474051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
